JP7643466B2 - Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途 - Google Patents

Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途 Download PDF

Info

Publication number
JP7643466B2
JP7643466B2 JP2022567355A JP2022567355A JP7643466B2 JP 7643466 B2 JP7643466 B2 JP 7643466B2 JP 2022567355 A JP2022567355 A JP 2022567355A JP 2022567355 A JP2022567355 A JP 2022567355A JP 7643466 B2 JP7643466 B2 JP 7643466B2
Authority
JP
Japan
Prior art keywords
mmol
general formula
mixture
give
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524547A (ja
JP2023524547A5 (https=
Inventor
章人 角内
周平 梅村
正樹 浅田
アナトリー ルビンスキー，
ヤン チャン，
秀典 ▲高▼橋
ゴラン クリロフ，
大吾 猪山
カイル コンゼ，
マッツ スベンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of JP2023524547A publication Critical patent/JP2023524547A/ja
Publication of JP2023524547A5 publication Critical patent/JP2023524547A5/ja
Priority to JP2024173464A priority Critical patent/JP7643632B2/ja
Priority to JP2025029239A priority patent/JP2025081677A/ja
Application granted granted Critical
Publication of JP7643466B2 publication Critical patent/JP7643466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022567355A 2020-05-07 2021-05-06 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途 Active JP7643466B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024173464A JP7643632B2 (ja) 2020-05-07 2024-10-02 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途
JP2025029239A JP2025081677A (ja) 2020-05-07 2025-02-26 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088925 2020-05-07
CN2020088925 2020-05-07
PCT/CN2021/091843 WO2021223699A1 (en) 2020-05-07 2021-05-06 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024173464A Division JP7643632B2 (ja) 2020-05-07 2024-10-02 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途

Publications (3)

Publication Number Publication Date
JP2023524547A JP2023524547A (ja) 2023-06-12
JP2023524547A5 JP2023524547A5 (https=) 2024-04-17
JP7643466B2 true JP7643466B2 (ja) 2025-03-11

Family

ID=76159223

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022567355A Active JP7643466B2 (ja) 2020-05-07 2021-05-06 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途
JP2024173464A Active JP7643632B2 (ja) 2020-05-07 2024-10-02 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途
JP2025029239A Withdrawn JP2025081677A (ja) 2020-05-07 2025-02-26 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024173464A Active JP7643632B2 (ja) 2020-05-07 2024-10-02 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途
JP2025029239A Withdrawn JP2025081677A (ja) 2020-05-07 2025-02-26 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途

Country Status (14)

Country Link
US (3) US11691968B2 (https=)
EP (2) EP4471027A1 (https=)
JP (3) JP7643466B2 (https=)
KR (2) KR20260046494A (https=)
CN (1) CN115461338B (https=)
AU (1) AU2021268223B2 (https=)
BR (1) BR112022022005A2 (https=)
CA (1) CA3181604A1 (https=)
ES (1) ES3037418T3 (https=)
IL (1) IL297900B2 (https=)
MX (1) MX2022013692A (https=)
NZ (1) NZ793960A (https=)
TW (1) TWI895412B (https=)
WO (1) WO2021223699A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023070167A (ja) * 2021-11-05 2023-05-18 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999183A4 (en) * 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
ES3037418T3 (en) 2020-05-07 2025-10-01 Ono Pharmaceutical Co 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof
WO2025239445A1 (ja) * 2024-05-17 2025-11-20 小野薬品工業株式会社 認知症の行動および心理症状の予防、進行抑制および／または治療剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533440A (ja) 1998-12-23 2002-10-08 ファイザー・インク オピエート受容体リガンドとしての３−アザビシクロ［３．１．０．］ヘキサン誘導体
JP2010540675A (ja) 2007-10-09 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー キラルシス−イミダゾリン
JP2017530984A (ja) 2014-10-10 2017-10-19 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
JP5017103B2 (ja) 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
CN108341819B (zh) 2017-01-22 2021-06-15 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
EP3999183A4 (en) 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
ES3037418T3 (en) 2020-05-07 2025-10-01 Ono Pharmaceutical Co 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533440A (ja) 1998-12-23 2002-10-08 ファイザー・インク オピエート受容体リガンドとしての３−アザビシクロ［３．１．０．］ヘキサン誘導体
JP2010540675A (ja) 2007-10-09 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー キラルシス−イミダゾリン
JP2017530984A (ja) 2014-10-10 2017-10-19 ジェネンテック， インコーポレイテッド ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023070167A (ja) * 2021-11-05 2023-05-18 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物
JP7743829B2 (ja) 2021-11-05 2025-09-25 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物

Also Published As

Publication number Publication date
IL297900B2 (en) 2026-04-01
WO2021223699A1 (en) 2021-11-11
JP2023524547A (ja) 2023-06-12
IL297900B1 (en) 2025-12-01
CN115461338A (zh) 2022-12-09
IL297900A (en) 2023-01-01
US12269817B2 (en) 2025-04-08
EP4146645A1 (en) 2023-03-15
US20230271952A1 (en) 2023-08-31
TWI895412B (zh) 2025-09-01
CA3181604A1 (en) 2021-11-11
KR20260046494A (ko) 2026-04-07
TW202200571A (zh) 2022-01-01
JP7643632B2 (ja) 2025-03-11
JP2025081677A (ja) 2025-05-27
KR20230007352A (ko) 2023-01-12
AU2021268223B2 (en) 2025-10-09
AU2021268223A1 (en) 2022-12-08
CN115461338B (zh) 2024-02-20
US20250214984A1 (en) 2025-07-03
EP4471027A1 (en) 2024-12-04
BR112022022005A2 (pt) 2022-12-13
US20230109293A1 (en) 2023-04-06
JP2024177345A (ja) 2024-12-19
KR102937044B1 (ko) 2026-03-09
ES3037418T3 (en) 2025-10-01
EP4146645B1 (en) 2025-06-25
US11691968B2 (en) 2023-07-04
NZ793960A (en) 2025-12-19
MX2022013692A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
JP7643632B2 (ja) Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途
JP7786517B2 (ja) Ｋｄｍ５阻害活性を有する化合物およびその医薬用途
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
IL285246B2 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
JP2024128038A (ja) Ａｂｈｄ６アンタゴニスト
EP3877384A1 (en) Chemical compounds
JP7743829B2 (ja) Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物
RU2840256C1 (ru) Соединение, обладающее ингибирующей активностью в отношении kdm5, и его фармацевтическое применение
KR20230065914A (ko) Kdm5 억제 활성을 갖는 화합물을 포함하는 약학 조성물
TWI907744B (zh) 包含具有kdm5抑制活性之化合物之醫藥組合物
HK40083699A (en) 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof
HK40083699B (zh) 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途
JP2022101520A (ja) Ｅｐ２アンタゴニストを含有する医薬組成物
JP2024052624A (ja) Ａｂｈｄ６アンタゴニストを含有する医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240405

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250210

R150 Certificate of patent or registration of utility model

Ref document number: 7643466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150